Advertisement

New antimalarial agents derived from nonlinear phenoxazine ring system

  • Mercy A. EzeokonkwoEmail author
  • Sunday N. Okafor
  • Onyinyechi N. Ogbonna
  • Efeturi A. Onoabedje
  • Fidelia N. Ibeanu
  • Evelyn U. Godwin-Nwakwasi
  • Benjamin E. Ezema
Original Research
  • 7 Downloads

Abstract

In vivo antimalarial screening of nine nonlinear phenoxazine compounds was carried out on the blood stages of Plasmodium berghei using standard methods. The activities of the compounds were compared with that of quinine as a standard antimalarial drug. LD50 and histopathological studies were also done. Molecular docking studies were carried out on four different protein targets of Plasmodium spp. The effects of these compounds on the hematological parameters (Hemoglobin, Hb; packed cell volume, PCV; white blood cells, WBC; and red blood cells, RBC) were also evaluated. The in vivo antimalarial studies showed that all the synthesized compounds had significant parasitaemia load reduction (89.00–94.05%) at 200 mg/ml when compared with the control, with (2-aminophenoxyl)benzo[a]phenoxazin-5-one 3b showing the highest activity. There was no significant difference in the activities of these compounds compared with the standard drug used (96%). The LD50 was found to be ≥5000 mg/kg. Histopathological studies showed a significant restoration of the liver intoxicated with malaria parasite after 5 days. The hematological analysis showed normal values for Hb, PCV, WBC, and RBC in the course of the treatment. The compounds showed more binding affinities for the P. falciparum receptors than the standard drug. The nine synthesized nonliner phenoxazine compounds had significant antimalarial activities and did not significantly affect the hematological parameters. They showed strong binding affinity to the parasite receptors. Hence, they are good candidates for antimalarial drugs. More preclinical investigations are needed.

Keywords

Nonlinear phenoxazine Plasmodium spp Binding affinity Molecular docking Antimalarial Parasitaemia 

Abbreviations

1CET

lactate dehydrogenase

3QS1

plasmepsin I

1LS5

plasmepsin II

1SME

plasmepsin IV

STD

standard drug

MW

molecular weight

NoRB

number of rotatable bonds

logP

partition coefficient

HBA

number of hydrogen bond acceptors

HBD

number of hydrogen bond donors

nViolation

number of violation

TPSA

total polar surface area

NC

normal control

NP

no parasitaemia

UG

untreated group

Hb

Hemoglobin

PCV

packed cell volume

RBC

red blood cell

WBC

white blood cell

Notes

Acknowledgements

The authors are grateful to the faculty of Veterinary Medicine Department of University of Nigeria, Nsukka for providing the malaria parasite—Plasmodium berghei used in the study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conlict of interest.

Ethics approval

The ethical clearance to use rats was in accordance with the University of Nigeria Ethics Committee on the use of laboratory animals, registered by the National Health Research Ethics Committee (NHREC) of Nigeria, with the number; NHREC/05/01/2008B.

References

  1. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE (2002) Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 99:990–995CrossRefGoogle Scholar
  2. Barness EC, Bezerra-Gomez P, Nett M, Dandamycin HC, Chandrananimycin E (2015) Benzoxazines from streptomycesgriseus. J Antibiot 68:463CrossRefGoogle Scholar
  3. Binkowski TA, Naghibzadeg S, Liang J (2003) CASTp computed atlas of surface topography of proteins. Nucleic Acids Res 31:3352–3355CrossRefGoogle Scholar
  4. Chaikuad A, Fairweather V, Conners R, Joseph-Horne T, Turgut-Balik D, Brady RL (2005) Structure of lactate dehydrogenase from Plasmodium vivax: complexes with NADH and APADH. Biochemistry 44:16221–16228CrossRefGoogle Scholar
  5. David AF, Philip JR, Simon LC, Reto B, Solomon N (2004) Nat Rev 3:509–520Google Scholar
  6. Dacie JV, Lewis SM (2000) Practical Haematology. 7th ed. London: Churchill Livingstone. pp. 837–852Google Scholar
  7. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467CrossRefGoogle Scholar
  8. Ezeokonkwo MA, Eze CC, Okafor SN, Onoabedje EA, Godwin-Nwakwasi EU, Ibeanu FN (2018) Diazabenzo[a]phenoxazone sulphonamides: synthesis, in-silico and in-vitro antimicrobial studies. Med Chem Res.  https://doi.org/10.1007/s00044-018-2251-4
  9. Ezeokonkwo MA, Ogbonna ON, Okafor SN, Godwin-Nwakwasi EU, Ibeanu FN, Okoro UC (2017) Angular phenozaxine ethers as potent multi-microbial targets inhibitors: design, synthesis, and molecular docking studies. Front Chem 5:107.  https://doi.org/10.3389/fchem.2017.00107 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S (2004) Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 3(6):509–520CrossRefGoogle Scholar
  11. Gowthaman R, Duraisamy S, Kalita MK, Gupta DA (2015) Database for Plasmodium falciparum protein models. Bioinformation 1:50–51CrossRefGoogle Scholar
  12. Jian-Feng G, Chika A, Mei Y, Abu BM, Jun L, Nasser SM, Ismail SW, Marcel K, Reto B, Susan AC, Tien N, Julia M, Isamu I, Masataka I (2010) Discovery of novel benzo[a]phenoxazine SSJ-183 as a drug candidate for malaria. ACS Med Chem Lett 1:360–364.  https://doi.org/10.1021/ml100120a CrossRefGoogle Scholar
  13. Nagarajaram HA, Iengar P, Ghosh I (2005) In silico approach to antimalarial drug discovery: Design of selective inhibitor to Plasmodium falciparum aspartic proteases. Front Biophys 6:168–181Google Scholar
  14. Ochei J, Kolhatkar A (2008) Medical Laboratory Sciences, Theory and practice. Tata McGraw-Hill Publishing Co. Ltd, New Delhi, pp. 321–324Google Scholar
  15. Okafor CO (1986) Synthesis, properties and uses of angular phenoxazines. Dyes Pigments 7(2):103–131.  https://doi.org/10.1016/0143-7208(86)85003-3 CrossRefGoogle Scholar
  16. Olasehinde GI, Ojurongbe DO, Akinjogunla OJ, Egwari LO, Adeyeba AO (2015) Prevalence of malaria and predisposing factors to antimalarial drug resistance in Southwestern Nigeria. Res J Parasitol 10:92–101CrossRefGoogle Scholar
  17. Onoabedje EA, Okoro UC, Sarkar A, Knight DW (2016) Synthesis and structure of new alkynyl derivatives of phenothiazine and phenoxazine J Sulfur Chem 37(3):269–281.  https://doi.org/10.1080/17415993,2015.1131827 CrossRefGoogle Scholar
  18. Osonuga IO, Osonuga OA, Osonuga A, Onadeko AA, Osonuga AA (2012) Effect of artemether on hematological parameters of healthy and uninfected adult Wistar rats. Asian Pac J Trop Biomed 2(6):493–495.  https://doi.org/10.1016/S2221-1691(12)60083-5 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Read JA, Wilkinson KW, Tranter R, Sessions RB, Brady RL (1999) Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem 274(15):10213–10218CrossRefGoogle Scholar
  20. Silva AM, Lee AY, Gulnik SV, Majer P, Collins J, Bhat TN, Collins PJ, Cachau RE, Luker KE, Gluzman IY, Francis SE, Oksman A, Goldberg DE, Erickson JW (1996) Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci USA 93:10034–10039CrossRefGoogle Scholar
  21. The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLCGoogle Scholar
  22. Van de Waterbeemd H, Camenish G, Folkers G, Chretien JR, Raevsky OA (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding characteristics. J Drug Target 6:151–165CrossRefGoogle Scholar
  23. Wang Q, Zhang YX, Wang M, Tan Y, Hu X, He H, Xiao C, You X, Wang Y, Gan M (2017) Neo-actinomycins A and B, natural antinomycins bearing the 5H-oxazolo[4,5-b]phenoxazine chromophore from marine derived Streptomyces species IMBO94. Sci Rep 7:3591.  https://doi.org/10.1038/s41598-01703769-8 CrossRefPubMedPubMedCentralGoogle Scholar
  24. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010a. apps.who.int › All› Medicine Access and Rational Use › Antimicrobial Drug Resistance Google Scholar
  25. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: World Health Organization; 2010b. https://www.who.int/malaria/publications/atoz/9789241500470/en/
  26. World Health Organization, “WHO guidelines for the treatment of malaria,” World Malaria Report, World Health Organization, Geneva, Switzerland, 2011. http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
  27. World Health Organization (WHO): World Malaria Report 2015. https://www.who.int/malaria/publications/world-malaria-report-2015/report/en/
  28. Wu YS, Lei LM, Li M (2005) Evaluation of a parasite lactate dehydrogenase-based colloid gold-immunochromatography assay for diagnosis of Plasmodium falciparum. Di Yi Jun Yi Da Xue Xue Bao 25:761–765PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mercy A. Ezeokonkwo
    • 1
    Email author
  • Sunday N. Okafor
    • 2
  • Onyinyechi N. Ogbonna
    • 3
  • Efeturi A. Onoabedje
    • 1
  • Fidelia N. Ibeanu
    • 4
  • Evelyn U. Godwin-Nwakwasi
    • 5
  • Benjamin E. Ezema
    • 1
  1. 1.Department of Pure and Industrial ChemistryUniversity of NigeriaNsukkaNigeria
  2. 2.Department of Pharmaceutical and Medicinal ChemistryUniversity of NigeriaNsukkaNigeria
  3. 3.Evangel UniversityAkaezeNigeria
  4. 4.Natural Science Unit, School of General StudiesUniversity of NigeriaNsukkaNigeria
  5. 5.Department of ChemistryGregory UniversityUturuNigeria

Personalised recommendations